The mammalian target of rapamycin (mTOR) inhibitor everolimus can restrict cell growth and proliferation and proved effective in reducing the volume of subependymal giant cell astrocytomas in a phase III trial (19). This evidence concerns the gene MTOR and astrocytoma (excluding glioblastoma).